Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045"

Affiliations

• ¹ Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
• ² Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Korea.
• ³ Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
• ⁴ Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
• ⁵ Department of Clinical Epidemiology & Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, Korea.
• ⁶ Department of Health Sciences and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Korea.
• ⁷ Samsung Genome Institute, Samsung Medical Center, Seoul, Korea.
• ⁸ Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
• ⁹ Geninus Inc., Seoul, Korea.